

(70147)

<b>Medical Benefit</b>		<b>Effective Date:</b> 04/01/18	<b>Next Review Date:</b> 11/20
<b>Preauthorization</b>	No	<b>Review Dates:</b> 04/07, 05/08, 05/09, 03/10, 03/11, 07/11, 07/12, 9/12, 05/13, 01/14, 01/15, 11/15, 11/16, 11/17, 11/18, 11/19	

**Preauthorization is not required.**

*The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.*

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> <li>Who are adults with morbid obesity</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Gastric bypass</li> <li>Laparoscopic adjustable gastric banding</li> <li>Sleeve gastrectomy</li> <li>Biliopancreatic diversion with duodenal switch</li> <li>Biliopancreatic diversion without duodenal switch</li> <li>Vertical-banded gastroplasty</li> <li>Laparoscopic gastric plication</li> <li>Single anastomosis duodenoileal bypass with sleeve gastrectomy</li> <li>Duodenojejunal sleeve</li> <li>Intragastric balloon devices</li> <li>Aspiration therapy device</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Standard medical care</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Change in disease status</li> <li>Functional outcomes</li> <li>Health status measures</li> <li>Quality of life</li> <li>Treatment-related mortality</li> <li>Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>Who are adults with morbid obesity</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Two-stage bariatric surgery procedures</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>One-stage bariatric surgery procedure</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Change in disease status</li> <li>Functional outcomes</li> <li>Health status measures</li> <li>Quality of life</li> <li>Treatment-related mortality</li> <li>Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>Who are adults with morbid obesity and failed bariatric surgery</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>revision bariatric surgery</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Standard medical care</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Change in disease status</li> <li>Functional outcomes</li> <li>Health status measures</li> <li>Quality of life</li> <li>Treatment-related mortality</li> <li>Treatment-related morbidity</li> </ul>

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> <li>Who are diabetic and not morbidly obese</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Gastric bypass</li> <li>Sleeve gastrectomy</li> <li>Biliopancreatic diversion</li> <li>Adjustable gastric banding</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Standard medical care</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Change in disease status</li> <li>Functional outcomes</li> <li>Health status measures</li> <li>Quality of life</li> <li>Treatment-related mortality</li> <li>Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>Who are not diabetic and not morbidly obese</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Any bariatric surgery procedure</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Standard medical care</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Change in disease status</li> <li>Functional outcomes</li> <li>Health status measures</li> <li>Quality of life</li> <li>Treatment-related mortality</li> <li>Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>Who are adolescent children with morbid obesity</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Gastric bypass, laparoscopic adjustable gastric banding, or sleeve gastrectomy</li> <li>Bariatric surgery other than gastric bypass, laparoscopic adjustable gastric banding or sleeve gastrectomy</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Standard medical care</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Change in disease status</li> <li>Functional outcomes</li> <li>Health status measures</li> <li>Quality of life</li> <li>Treatment-related mortality</li> <li>Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>Who are preadolescent children with morbid obesity</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Bariatric surgery</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Standard medical care</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Change in disease status</li> <li>Functional outcomes</li> <li>Health status measures</li> <li>Quality of life</li> <li>Treatment-related mortality</li> <li>Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>With morbid obesity and a preoperative diagnosis of hiatal hernia</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Hiatal hernia repair with bariatric surgery</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Bariatric surgery alone</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Change in disease status</li> <li>Functional outcomes</li> <li>Health status measures</li> <li>Quality of life</li> <li>Treatment-related mortality</li> <li>Treatment-related morbidity</li> </ul>

## DESCRIPTION

Bariatric surgery is a treatment for morbid obesity in patients who fail to lose weight with conservative measures. There are numerous gastric and intestinal surgical techniques available. While these techniques have heterogeneous mechanisms of action, the result is a smaller gastric pouch that leads to restricted eating. However, these surgeries may lead to malabsorption of nutrients or eventually to metabolic changes.

## SUMMARY OF EVIDENCE

### ADULTS WITH MORBID OBESITY

For individuals who are adults with morbid obesity who receive gastric bypass, the evidence includes randomized controlled trials (RCTs), observational studies, and systematic reviews. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. TEC Assessments and other systematic reviews of RCTs and observational studies found that gastric bypass improves health outcomes, including weight loss and remission of type 2 diabetes. A TEC Assessment found similar weight loss with open and laparoscopic gastric bypass. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are adults with morbid obesity who receive laparoscopic adjustable gastric banding (LAGB), the evidence includes RCTs, observational studies, and systematic reviews. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Systematic reviews of RCTs and observational studies have found that LAGB is a reasonable alternative to gastric bypass. There is less weight loss with LAGB than with gastric bypass, but LAGB is less invasive and is associated with fewer serious adverse events. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are adults with morbid obesity who receive sleeve gastrectomy (SG), the evidence includes RCTs, observational studies (evaluating SG alone and comparing SG with gastric bypass), as well as systematic reviews. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Systematic reviews of RCTs and observational studies have found that SG results in substantial weight loss and that this weight loss is durable for at least five years. A meta-analysis found that short-term weight loss was similar after SG compared with gastric bypass. Long-term weight loss was greater after gastric bypass, but SG is associated with fewer adverse events. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are adults with morbid obesity who receive biliopancreatic diversion (BPD) with duodenal switch, the evidence includes nonrandomized comparative studies, observational studies, and a systematic review. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Nonrandomized comparative studies have found significantly higher weight loss after BPD with duodenal switch compared with gastric bypass at one year. A large case series found sustained weight loss after seven years. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are adults with morbid obesity who receive BPD without duodenal switch, the evidence includes observational studies and systematic reviews. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. A TEC Assessment reviewed the available observational studies and concluded that weight loss was similar after BPD without a duodenal switch or gastric bypass. However, concerns have been raised about complications associated with BPD without duodenal switch, especially long-term nutritional and vitamin deficiencies. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are adults with morbid obesity who receive vertical-banded gastroplasty, the evidence includes observational studies and systematic reviews. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. A TEC Assessment identified eight nonrandomized comparative studies evaluating vertical-banded gastroplasty, and these studies found that weight loss was significantly greater with open gastric bypass. Moreover,

vertical-banded gastroplasty has relatively high rates of complications, revisions, and reoperations. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are adults with morbid obesity who receive two-stage bariatric surgery procedures, the evidence includes a small RCT and observational studies. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. There is a lack of evidence that two-stage bariatric procedures improve outcomes compared with one-stage procedures. The small RCT compared intragastric balloon (IGB) plus gastric bypass with the standard of care plus gastric bypass and did not detect a difference in weight loss at six months post-surgery. Case series have shown relatively high complication rates in two-stage procedures, and patients are at risk of complications in both stages. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are adults with morbid obesity who receive laparoscopic gastric plication, the evidence includes two RCTs, observational studies, and systematic reviews. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. A 2014 systematic review only identified a small nonrandomized comparative study comparing laparoscopic gastric plication with other bariatric surgery procedures. Since the systematic review, two RCTs have been published, one comparing laparoscopic gastric plication with a sham procedure and another comparing laparoscopic gastric plication with SG. Laparoscopic gastric plication was more effective than sham at one-year follow-up and equally effective as SG at two-year follow-up. Additional comparative studies and RCTs with longer follow-up are needed to permit conclusions about the safety and efficacy of laparoscopic gastric plication. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are adults with morbid obesity who receive single anastomosis duodenoileal bypass with SG (SADI-S), the evidence includes observational studies. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. No controlled trials have evaluated SADI-S. There are a few case series, the largest of which had fewer than 100 patients. A retrospective chart review of patients receiving gastric bypass, BPD, and SADI-S, reported that among patients without diabetes, SADI-S was more effective in weight loss and cholesterol outcomes than gastric bypass. Among patients with diabetes, SADI-S and BDP had higher remission rates than gastric bypass. Comparative studies and especially RCTs are needed to permit conclusions about the safety and efficacy of SADI-S. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are adults with morbid obesity who receive duodenojejunal sleeve, the evidence includes RCTs and systematic reviews. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. A systematic review of duodenojejunal sleeves included five RCTs and found significantly greater short-term weight loss (12-24 weeks) with the sleeves compared with medical therapy. There was no significant difference in symptoms associated with diabetes. All RCTs were small and judged by systematic reviewers to be at high-risk of bias. High-quality comparative studies are needed to permit conclusions on the safety and efficacy of the procedure. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are adults with morbid obesity who receive IGB devices, the evidence includes RCTs, systematic reviews, and case series. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. RCTs assessing the two IGB devices approved by the Food and Drug Administration have found significantly greater weight loss with IGB than with sham treatment or lifestyle therapy alone after six months (maximum length of device use). Some adverse events were reported, mainly related to accommodation of the balloon in the stomach; in a minority of cases, these adverse events were severe. One RCT followed patients for an additional six months after IGB removal and found sustained weight loss. There are limited data on the durability of weight loss in the long-term. Comparative data are lacking. A large case series found that patients gradually regained weight over

time. Moreover, it is unclear how six months of IGB use would fit into a long-term weight loss and maintenance intervention. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are adults with morbid obesity who receive an aspiration therapy device, the evidence includes an RCT and case series. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. The RCT found significantly greater weight loss with aspiration therapy than lifestyle therapy at one year. One small case series reported on 15 patients at two years. The total amount of data on aspiration therapy remains limited and additional studies are needed before conclusions can be drawn about the effects of treatment on weight loss, metabolism and nutrition and long-term durability of treatment. The evidence is insufficient to determine the effects of the technology on health outcomes.

#### REVISION BARIATRIC SURGERY

For individuals who are adults with morbid obesity and failed bariatric surgery who receive revision bariatric surgery, the evidence includes case series and registry data. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Case series have shown that patients receiving revision bariatric surgery experienced satisfactory weight loss. Data from a multinational bariatric surgery database has found that corrective procedures following primary bariatric surgery are relatively uncommon but generally safe and efficacious. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

#### ADULTS WITH TYPE 2 DIABETES

For individuals who are diabetic and not morbidly obese who receive gastric bypass, SG, BPD, or LAGB, the evidence includes RCTs, nonrandomized comparative studies, and case series. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Systematic reviews of RCTs and observational studies have found that certain types of bariatric surgery are more efficacious than medical therapy as a treatment for type 2 diabetes in obese patients, including those with a body mass index (BMI) between 30 and 34.9 kg/m<sup>2</sup>. The greatest amount of evidence is on gastric bypass. Systematic reviews have found significantly greater remission rates of diabetes, decrease in hemoglobin A1c levels, and decrease in BMI with bariatric surgery than with nonsurgical treatment. The efficacy of surgery is balanced against the short-term risks of the surgical procedure. Most RCTs in this population have one to three years of follow-up; one RCT that included patients with BMI between 30 and 34.9 kg/m<sup>2</sup> had five-year follow-up data. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

#### NONDIABETIC AND NONOBESE ADULTS

For individuals who are not diabetic and not morbidly obese who receive any bariatric surgery procedure, the evidence includes RCTs, nonrandomized comparative studies, and case series. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. There is limited evidence for bariatric surgery in patients who are not diabetic or morbidly obese. A few small RCTs and case series have reported a loss of weight and improvements in comorbidities for this population. However, the evidence does not permit conclusions on the long-term risk-benefit ratio of bariatric surgery in this population. The evidence is insufficient to determine the effects of the technology on health outcomes.

#### ADOLESCENT CHILDREN WITH MORBID OBESITY

##### Gastric Bypass, LAGB, or SG

For individuals who are adolescent children with morbid obesity who receive gastric bypass, or LAGB, or SG, the evidence includes RCTs, observational studies, and systematic reviews. Relevant outcomes are overall survival,

change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Systematic reviews of studies on bariatric surgery in adolescents, who mainly received gastric bypass or LAGB or SG, found significant weight loss and reductions in comorbidity outcomes with bariatric surgery. For bariatric surgery in the adolescent population, although data are limited on some procedures, studies have generally reported that weight loss and reduction in risk factors for adolescents are similar to that for adults. Most experts and clinical practice guidelines have recommended that bariatric surgery in adolescents be reserved for individuals with severe comorbidities, or for individuals with a BMI greater than 50 kg/m<sup>2</sup>. Also, greater consideration should be placed on the patient developmental stage, on the psychosocial aspects of obesity and surgery, and on ensuring that the patient can provide fully informed consent. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

#### Bariatric Surgery Other Than Gastric Bypass, LAGB, or SG

For individuals who are adolescent children with morbid obesity who receive bariatric surgery other than gastric bypass, or LAGB, or SG, the evidence includes systematic reviews and a cohort study. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Studies using bariatric surgery other than gastric bypass, LAGB, or SG, have small sample sizes. Results from a meta-analysis including patients using other procedures have shown significant improvements in BMI reduction, fasting blood insulin, and total cholesterol, although the estimates have wide confidence intervals, limiting interpretation. The evidence is insufficient to determine the effects of the technology on health outcomes.

#### PREADOLESCENT CHILDREN WITH MORBID OBESITY

For individuals who are preadolescent children with morbid obesity who receive bariatric surgery, the evidence includes no studies focused on this population. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Several studies of bariatric surgery in adolescents have also included children younger than 12 years old, but findings were not reported separately for preadolescent children. Moreover, clinical practice guidelines have recommended against bariatric surgery for preadolescent children. The evidence is insufficient to determine the effects of the technology on health outcomes.

#### HIATAL HERNIA REPAIR WITH BARIATRIC SURGERY

For individuals with morbid obesity and a preoperative diagnosis of a hiatal hernia who receive hiatal hernia repair with bariatric surgery, the evidence includes cohort studies and case series. Relevant outcomes are overall survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. Results from the cohort studies and case series have shown that, when a preoperative diagnosis of a hiatal hernia has been present, repairing the hiatal hernia during bariatric surgery resulted in fewer complications. However, the results are limited to individuals with a preoperative diagnosis. There was no evidence on the use of hiatal hernia repair when the hiatal hernia diagnosis is incidental. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

### POLICY

#### BARIATRIC SURGERY IN ADULTS WITH MORBID OBESITY

The following bariatric surgery procedures may be considered **medically necessary** for the treatment of morbid obesity (see Policy Guidelines for patient selection criteria) in adults who have failed weight loss by conservative measures\*:

- Open gastric bypass using a Roux-en-Y anastomosis

- Laparoscopic gastric bypass using a Roux-en-Y anastomosis
- Laparoscopic adjustable gastric banding
- Sleeve gastrectomy
- Open or laparoscopic biliopancreatic bypass (i.e., Scopinaro procedure) with duodenal switch.

Bariatric surgery should be performed in appropriately selected patients, by surgeons who are adequately trained and experienced in the specific techniques used, and in institutions that support a comprehensive bariatric surgery program, including long-term monitoring and follow-up post-surgery.

The following bariatric surgery procedures are considered **investigational** for the treatment of morbid obesity in adults who have failed weight loss by conservative measures\*:

- Vertical-banded gastroplasty
- Gastric bypass using a Billroth II type of anastomosis (mini-gastric bypass)
- Biliopancreatic diversion without duodenal switch
- Long-limb gastric bypass procedure (i.e., greater than 150 cm)
- Two-stage bariatric surgery procedures (e.g., sleeve gastrectomy as initial procedure followed by biliopancreatic diversion at a later time)
- Laparoscopic gastric plication
- Single anastomosis duodenoileal bypass with sleeve gastrectomy.

The following endoscopic procedures are **investigational** as a primary bariatric procedure or as a revision procedure (i.e., to treat weight gain after bariatric surgery to remedy large gastric stoma or large gastric pouches):

- Insertion of the StomaphyX™ device
- Endoscopic gastroplasty
- Use of an endoscopically placed duodenojejunal sleeve
- Intra-gastric balloons
- Aspiration therapy device.

#### BARIATRIC SURGERY IN PATIENTS WITH A BODY MASS INDEX LESS THAN 35 KG/M<sup>2</sup>

Bariatric surgery is considered **not medically necessary** for patients with a body mass index less than 35 kg/m<sup>2</sup>.

#### REVISION BARIATRIC SURGERY

Revision surgery to address perioperative or late complications of a bariatric procedure is considered **medically necessary**. They include, but are not limited to, staple-line failure, obstruction, stricture, nonabsorption resulting in hypoglycemia or malnutrition, weight loss of 20% or more below ideal body weight, and band slippage that cannot be corrected with manipulation or adjustment (see Policy Guidelines).

Revision of a primary bariatric procedure that has failed due to dilation of the gastric pouch or dilation proximal to an adjustable gastric band (documented by upper gastrointestinal examination or endoscopy) is considered **medically necessary** if the initial procedure was successful in inducing weight loss prior to pouch dilation and the patient has been compliant with a prescribed nutrition and exercise program.

#### BARIATRIC SURGERY IN ADOLESCENTS

Bariatric surgery in adolescents may be considered **medically necessary** according to the same weight-based

criteria used for adults, but greater consideration should be given to psychosocial and informed consent issues (see Policy Guidelines). In addition, any devices used for bariatric surgery must be in accordance with the U.S. Food and Drug Administration-approved indications.

#### BARIATRIC SURGERY IN PREADOLESCENT CHILDREN

Bariatric surgery is considered **investigational** for the treatment of morbid obesity in preadolescent children.

#### CONCOMITANT HIATAL HERNIA REPAIR WITH BARIATRIC SURGERY

Repair of a hiatal hernia at the time of bariatric surgery may be considered **medically necessary** for patients who have a preoperatively-diagnosed hiatal hernia with indications for surgical repair (See Policy Guidelines).

Repair of a hiatal hernia that is diagnosed at the time of bariatric surgery, or repair of a pre-operatively diagnosed hiatal hernia in patients who do not have indications for surgical repair, is considered **investigational**.

\*Conservative measures are defined as non-surgical treatment including dietary counseling and some amount of exercise under the supervision of a physician. (If, in the opinion of the physician, the patient's condition precludes the ability to exercise, this will be taken into consideration under individual medical director review on a case by case basis.) Conservative measures need to be documented as refractory for at least six months. There should be a failure to sustain a five to 10% or more reduction in body weight prior to consultation for bariatric surgery. The patient should be screened carefully by the appropriate mental health professional with regard to their ability to follow up with post op requirements. There should be no evidence of alcohol or drug abuse and it is strongly recommended that the bariatric surgeon urge the patient to remain nicotine free for six weeks prior to surgery.

### POLICY GUIDELINES

#### PATIENT SELECTION CRITERIA

Morbid obesity is defined as a body mass index (BMI) of 40 kg/m<sup>2</sup> or more or a BMI of 35 kg/m<sup>2</sup> or more with at least one clinically significant obesity-related disease such as diabetes mellitus, obstructive sleep apnea, coronary artery disease, or hypertension for which these complications or diseases are not controlled by best practice medical management.

While there is limited evidence on which to assess the long-term impacts of bariatric surgery for patients younger than age 18 years, very severely obese (BMI greater than or equal to 40 kg/m<sup>2</sup>) adolescents with serious obesity-related comorbidities that are poorly controlled, or who have a BMI of 50 kg/m<sup>2</sup> or greater with less severe comorbidities may be considered for bariatric surgery. U.S. Food and Drug Administration (FDA) pre-market approval for the LAP-BAND® System indicates it is intended for severely obese adult patients. (The clinical study submitted to FDA for approval of the LAP-BAND was restricted to adults ages 18-55 years.)

Patients should have documented failure to respond to conservative measures for weight reduction prior to consideration of bariatric surgery and these attempts should be reviewed by the practitioner prior to seeking approval for the surgical procedure. As a result, some centers require active participation in a formal weight reduction program that includes frequent documentation of weight, dietary regimen, and exercise. However, there is lack of evidence on the optimal timing, intensity and duration of nonsurgical attempts at weight loss, and whether a medical weight loss program immediately preceding surgery improves outcomes.

Patients with a BMI of 50 kg/m<sup>2</sup> or more need a bariatric procedure to achieve greater weight loss. Thus, use of adjustable gastric banding which results in less weight loss, should be most useful as a procedure for patients with a BMI less than 50 kg/m<sup>2</sup>. Malabsorptive procedures, although they produce more dramatic weight loss, potentially result in nutritional complications, and the risks and benefits of these procedures must be carefully weighed in light of the treatment goals for each patient.

Patients who undergo adjustable gastric banding and fail to achieve adequate weight loss must show evidence of postoperative compliance with diet and regular bariatric visits prior to consideration of a second bariatric procedure.

#### CONSIDERATIONS FOR BARIATRIC SURGERY IN ADOLESCENTS

Guidelines for bariatric surgery in adolescents are not uniform, with variability in weight-based criteria, ranging from a BMI of 35 kg/m<sup>2</sup> with comorbidities to a BMI of 50 kg/m<sup>2</sup>. Most guidelines use weight-based criteria that parallel those for adults.

In addition to the weight-based criteria, there is greater emphasis on issues of developmental maturity, psychosocial status, and informed consent for adolescent patients. All guidelines mention these issues, but recommendations are not uniform for addressing them. The following are examples from U.S. guidelines published since 2008 that address issues of maturity and psychosocial status.

##### Endocrine Society

- The child has attained Tanner 4 or 5 pubertal development and final or near-final adult height.
- Psychological evaluation confirms the stability and competence of the family unit.
- The patient demonstrates the ability to adhere to the principles of healthy dietary and activity habits (August et al, 2008).

##### Institute for Clinical Systems Improvement

The Institute for Clinical Systems Improvement's 2013 obesity guidelines have indicated that bariatric surgery should only be considered in the pediatric population under the following conditions (Fitch et al, 2013).

- "The child has a BMI >40 kg/m<sup>2</sup> or has BMI above 35 kg/m<sup>2</sup> with a significant, severe comorbidities such as type 2 diabetes mellitus, obstructive sleep apnea, or pseudotumor cerebri."
- "The child has attained Tanner 4 or 5 pubertal development or has a bone age ≥13 years in girls or ≥15 years in boys."
- "Failure of ≥ six months of organized attempts at weight management...."
- "The adolescent should have decisional capacity and also demonstrate commitment to comprehensive medical and psychological evaluation before and after surgery."
- "A supportive family environment...."

The choice of procedure in adolescents may also differ from adults, but there is a lack of consensus in guidelines or expert opinion as to the preferred procedure(s) for adolescents. The following factors should be considered in the choice of bariatric surgery in adolescents (Aikenhead et al, 2011):

- As in adults, laparoscopic gastric bypass is the most common procedure in adolescents.
- Devices used for laparoscopic adjustable gastric banding do not have FDA approval in the United States for individuals younger than age 18 years.
- Some guidelines for bariatric surgery in adolescents do not recommend biliopancreatic diversions in adolescents because of the greater frequency of nutritional deficiencies on long-term follow-up, but other guidelines do not specify that biliopancreatic diversion not be done in adolescents.

#### HIATAL HERNIA REPAIR GUIDELINES

The Society of American Gastrointestinal and Endoscopic Surgeons issued evidence-based guidelines for the management of hiatal hernia. (Kohn et al, 2013). The Society noted that the general methodologic quality of

available studies is low. Recommendations for indications for repair are as follows:

- “Repair of a type I hernia [sliding hiatal hernias, where the gastroesophageal junction migrates above the diaphragm] in the absence of reflux disease is not necessary” (moderate quality evidence, strong recommendation).
- “All symptomatic paraesophageal hiatal hernias should be repaired (high quality evidence, strong recommendation), particularly those with acute obstructive symptoms or which have undergone volvulus.”
- “Routine elective repair of completely asymptomatic paraesophageal hernias may not always be indicated. Consideration for surgery should include the patient’s age and comorbidities” (moderate quality evidence, weak recommendation).

### MEDICARE ADVANTAGE

The following procedures may be considered **medically necessary** when the individual has a body mass index (BMI)  $\geq 35$  kg/m<sup>2</sup>, has at least one comorbidity related to obesity (including type 2 diabetes mellitus) and has previously been unsuccessful with medical treatment for obesity:

- Laparoscopic Adjustable Gastric Banding,
- Gastric Bypass Surgery (open and laparoscopic Roux-en-Y),
- Open and laparoscopic Biliopancreatic Diversion with Duodenal Switch or Gastric Reduction Duodenal Switch, and
- Stand-alone laparoscopic sleeve gastrectomy (LSG).

The following are **investigational** for Medicare Advantage:

- Open vertical banded gastroplasty,
- Laparoscopic vertical banded gastroplasty,
- Open sleeve gastrectomy,
- Laparoscopic sleeve gastrectomy, not as a stand-alone service,
- Open adjustable gastric banding,
- Gastric balloon, and
- Intestinal bypass.

### BACKGROUND

#### BARIATRIC SURGERY

Bariatric surgery is performed to treat morbid (clinically severe) obesity. Morbid obesity is defined as a body mass index (BMI) greater than 40 kg/m<sup>2</sup> or a BMI greater than 35 kg/m<sup>2</sup> with associated complications including, but not limited to, diabetes, hypertension, or obstructive sleep apnea. Morbid obesity results in a very high-risk for weight-related complications, such as diabetes, hypertension, obstructive sleep apnea, and various types of cancers (for men: colon, rectal, prostate; for women: breast, uterine, ovarian), and a shortened lifespan. A morbidly obese man at age 20 can expect to live 13 fewer years than his counterpart with a normal BMI, which equates to a 22% reduction in life expectancy.

The first treatment of morbid obesity is dietary and lifestyle changes. Although this strategy may be effective in some patients, only a few morbidly obese individuals can reduce and control weight through diet and exercise. Most patients find it difficult to comply with these lifestyle modifications on a long-term basis.

When conservative measures fail, some patients may consider surgical approaches. A 1991 National Institutes of Health Consensus Conference defined surgical candidates as “those patients with a BMI of greater than 40 kg/m<sup>2</sup>, or greater than 35 kg/m<sup>2</sup> in conjunction with severe comorbidities such as cardiopulmonary complications or severe diabetes.”<sup>1</sup>

Resolution (cure) or improvement of type 2 diabetes after bariatric surgery and observations that glycemic control may improve immediately after surgery before a significant amount of weight is lost have promoted interest in a surgical approach to the treatment of type 2 diabetes. The various surgical procedures have different effects, and gastrointestinal rearrangement seems to confer additional antidiabetic benefits independent of weight loss and caloric restriction. The precise mechanisms are not clear, and multiple mechanisms may be involved. Gastrointestinal peptides, e.g., glucagon-like peptide-1, glucose-dependent insulinotropic peptide, and peptide YY, are secreted in response to contact with unabsorbed nutrients and by vagally mediated parasympathetic neural mechanisms. Glucagon-like peptide-1 is secreted by the L cells of the distal ileum in response to ingested nutrients and acts on pancreatic islets to augment glucose-dependent insulin secretion. It also slows gastric emptying, which delays digestion, blunts postprandial glycemia, and acts on the central nervous system to induce satiety and decrease food intake. Other effects may improve insulin sensitivity. Glucose-dependent insulinotropic peptide acts on pancreatic beta cells to increase insulin secretion through the same mechanisms as glucagon-like peptide-1, although it is less potent. Peptide YY is also secreted by the L cells of the distal intestine and increases satiety and delays gastric emptying.

#### TYPES OF BARIATRIC SURGERY PROCEDURES

The following summarizes the most common bariatric surgery procedures.

##### Open Gastric Bypass

The original gastric bypass surgeries were based on the observation that postgastrectomy patients tended to lose weight. The current procedure involves both a restrictive and a malabsorptive component, with the horizontal or vertical partition of the stomach performed in association with a Roux-en-Y procedure (i.e., a gastrojejunal anastomosis). Thus, the flow of food bypasses the duodenum and proximal small bowel. The procedure may also be associated with an unpleasant “dumping syndrome,” in which a large osmotic load delivered directly to the jejunum from the stomach produces abdominal pain and/or vomiting. The dumping syndrome may further reduce intake, particularly in “sweets eaters.” Surgical complications include leakage and operative margin ulceration at the anastomotic site. Because the normal flow of food is disrupted, there are more metabolic complications than with other gastric restrictive procedures, including iron deficiency anemia, vitamin B12 deficiency, and hypocalcemia, all of which can be corrected by oral supplementation. Another concern is the ability to evaluate the “blind” bypassed portion of the stomach. Gastric bypass may be performed with either an open or laparoscopic technique.

##### Adjustable Gastric Banding

Adjustable gastric banding involves placing a gastric band around the exterior of the stomach. The band is attached to a reservoir implanted subcutaneously in the rectus sheath. Injecting the reservoir with saline will alter the diameter of the gastric band; therefore, the rate-limiting stoma in the stomach can be progressively narrowed to induce greater weight loss, or expanded if complications develop. Because the stomach is not entered, the surgery and any revisions, if necessary, are relatively simple.

Complications include slippage of the external band or band erosion through the gastric wall. Adjustable gastric banding has been widely used in Europe. Two banding devices are approved by the Food and Drug Administration (FDA) for marketing in the United States. The first to receive FDA approval was the LAP-BAND (original

applicant, Allergan, BioEnterics, Carpinteria, CA; now Apollo Endosurgery, Austin, TX). The labeled indications for this device are as follows:

“The LAP-BAND® system is indicated for use in weight reduction for severely obese patients with a body mass index (BMI) of at least 40 or a BMI of at least 35 with one or more severe comorbid conditions, or those who are 100 lb or more over their estimated ideal weight according to the 1983 Metropolitan Life Insurance Tables (use the midpoint for medium frame). It is indicated for use only in severely obese adult patients who have failed more conservative weight-reduction alternatives, such as supervised diet, exercise and behavior modification programs. Patients who elect to have this surgery must make the commitment to accept significant changes in their eating habits for the rest of their lives.”

In 2011, FDA-labeled indications for the LAP-BAND were expanded to include patients with a BMI from 30 to 34 kg/m<sup>2</sup> with at least one obesity-related comorbid condition.

The second adjustable gastric banding device approved by FDA through the premarket approval process is the REALIZE® model (Ethicon Endo-Surgery, Cincinnati, OH). Labeled indications for this device are:

“The [REALIZE] device is indicated for weight reduction for morbidly obese patients and is indicated for individuals with a Body Mass Index of at least 40 kg/m<sup>2</sup>, or a BMI of at least 35 kg/m<sup>2</sup> with one or more comorbid conditions. The Band is indicated for use only in morbidly obese adult patients who have failed more conservative weight-reduction alternatives, such as supervised diet, exercise, and behavior modification programs.”

#### Sleeve Gastrectomy

A sleeve gastrectomy is an alternative approach to gastrectomy that can be performed on its own or in combination with malabsorptive procedures (most commonly biliopancreatic diversion [BPD] with duodenal switch). In this procedure, the greater curvature of the stomach is resected from the angle of His to the distal antrum, resulting in a stomach remnant shaped like a tube or sleeve. The pyloric sphincter is preserved, resulting in a more physiologic transit of food from the stomach to the duodenum and avoiding the dumping syndrome (overly rapid transport of food through the stomach into intestines) seen with distal gastrectomy. This procedure is relatively simple to perform and can be done as an open or laparoscopic procedure. Some surgeons have proposed the SG as the first in a two-stage procedure for very high-risk patients. Weight loss following SG may improve a patient’s overall medical status and, thus, reduce the risk of a subsequent more extensive malabsorptive procedure (e.g., BPD).

#### Biliopancreatic Diversion

The BPD procedure (also known as the Scopinaro procedure), developed and used extensively in Italy, was designed to address drawbacks of the original intestinal bypass procedures that have been abandoned due to unacceptable metabolic complications. Many complications were thought to be related to bacterial overgrowth and toxin production in the blind, bypassed segment. In contrast, BPD consists of a subtotal gastrectomy and diversion of the biliopancreatic juices into the distal ileum by a long Roux-en-Y procedure. The procedure consists of the following components:

- a. A distal gastrectomy induces temporary early satiety and/or the dumping syndrome in the early postoperative period, both of which limit food intake.
- b. A 200-cm long “alimentary tract” consists of 200 cm of ileum connecting the stomach to a common distal segment.
- c. A 300- to 400-cm “biliary tract” connects the duodenum, jejunum, and remaining ileum to the common distal segment.

- d. A 50- to 100-cm “common tract” is where food from the alimentary tract mixes with biliopancreatic juices from the biliary tract. Food digestion and absorption, particularly of fats and starches, are therefore limited to this small segment of bowel, creating selective malabsorption. The length of the common segment will influence the degree of malabsorption.

Because of the high incidence of cholelithiasis associated with the procedure, patients typically undergo an associated cholecystectomy.

Many potential metabolic complications are related to BPD, including, most prominently, iron deficiency anemia, protein malnutrition, hypocalcemia, and bone demineralization. Protein malnutrition may require treatment with total parenteral nutrition. Also, several case reports have noted liver failure resulting in death or liver transplant.

#### BPD With Duodenal Switch

The duodenal switch procedure is a variant of the BPD previously described. In this procedure, instead of performing a distal gastrectomy, a SG is performed along the vertical axis of the stomach. This approach preserves the pylorus and initial segment of the duodenum, which is then anastomosed to a segment of the ileum, similar to the BPD, to create the alimentary limb. Preservation of the pyloric sphincter is intended to ameliorate the dumping syndrome and decrease the incidence of ulcers at the duodenoileal anastomosis by providing a more physiologic transfer of stomach contents to the duodenum. The SG also decreases the volume of the stomach and decreases the parietal cell mass. However, the basic principle of the procedure is similar to that of the BPD, i.e., producing selective malabsorption by limiting the food digestion and absorption to a short common ileal segment.

#### Vertical-Banded Gastroplasty

Vertical-banded gastroplasty was formerly one of the most common gastric restrictive procedures performed in the United States but has now been replaced by other restrictive procedures due to high rates of revisions and reoperations. In this procedure, the stomach is segmented along its vertical axis. In order to create a durable reinforced and rate-limiting stoma at the distal end of the pouch, a plug of the stomach is removed, and a pro-pylene collar is placed through this hole and then stapled to itself. Because the normal flow of food is preserved, metabolic complications are uncommon. Complications include esophageal reflux, dilation, or obstruction of the stoma, with the latter two requiring reoperation. Dilation of the stoma is a common reason for weight regain. Vertical-banded gastroplasty may be performed using an open or laparoscopic approach.

#### Long-Limb Gastric Bypass (i.e., >150 cm)

Variations of gastric bypass procedures have been described, consisting primarily of long-limb Roux-en-Y procedures, which vary in the length of the alimentary and common limbs. For example, the stomach may be divided with a long segment of the jejunum (instead of ileum) anastomosed to the proximal gastric stump, creating the alimentary limb. The remaining pancreaticobiliary limb, consisting of stomach remnant, duodenum, and length of proximal jejunum, is then anastomosed to the ileum, creating a common limb of variable length in which the ingested food mixes with the pancreaticobiliary juices. While the long alimentary limb permits absorption of most nutrients, the short common limb primarily limits absorption of fats. The stomach may be bypassed in a variety of ways (e.g., resection or stapling along the horizontal or vertical axis). Unlike the traditional gastric bypass, which is a gastric restrictive procedure, these very long-limb Roux-en-Y gastric bypasses combine gastric restriction with some element of malabsorptive procedure, depending on the location of the anastomoses. Note that CPT code for gastric bypass explicitly describes a short limb (<150 cm) Roux-en-Y gastroenterostomy, and thus would not apply to long-limb gastric bypass.

## LAPAROSCOPIC MALABSORPTIVE PROCEDURE

### Weight Loss Outcomes

There is no uniform standard for reporting results of weight loss or for describing a successful procedure. Common methods of reporting the amount of body weight loss are the percent of ideal body weight achieved or percent of excess body weight (EBW) loss, with the latter most commonly reported. EBW is defined as actual weight minus “ideal weight” and “ideal weight” and is based on 1983 Metropolitan Life Insurance height-weight tables for “medium frame.”

These two reporting methods are generally preferred over the absolute amount of weight loss because they reflect the ultimate goal of surgery: to reduce weight to a range that minimizes obesity-related morbidity. Obviously, an increasing degree of obesity will require a greater amount of weight loss to achieve these target goals. There are different definitions of successful outcomes, but a successful procedure is often considered one in which at least 50% of EBW is lost, or when the patient returns to within 30% of ideal body weight. The results may also be expressed as the percentage of patients losing at least 50% of EBW. Table 1 summarizes the variations in reporting weight loss outcomes.

Table 1. Weight Loss Outcomes

Outcome Measure	Definition	Clinical Significance
Decrease in weight	Absolute difference in weight pre- and posttreatment	Unclear relation to outcomes, especially in morbidly obese
Decrease in BMI	Absolute difference in BMI pre- and posttreatment	May be clinically significant if change in BMI clearly leads to change in risk category
Percent EBW loss	Amount of weight loss divided by EBW	Has anchor to help frame clinical significance; unclear threshold for clinical significance
Percent patients losing >50% of EBW	Number of patients losing >50% EBW divided by total patients	Additional advantage of framing on per patient basis. Threshold for significance (>50%) arbitrary.
Percent ideal body weight	Final weight divided by ideal body weight	Has anchor to help frame clinical significance; unclear threshold for clinical significance

BMI: body mass index; EBW: excess body weight

### Durability of Weight Loss

Weight change (i.e., gain or loss) at yearly intervals is often reported. Weight loss at one year is considered the minimum length of time for evaluating these procedures; weight loss at three to five years is considered an intermediate time period for evaluating weight loss; and weight loss at five to ten years or more is considered to represent long-term weight loss following bariatric surgery.

### Short-Term Complications (Operative and Perioperative Complications <30 Days)

In general, the incidence of operative and perioperative complications is increased in obese patients, particularly in thromboembolism and wound healing. Other perioperative complications include anastomotic leaks, bleeding, bowel obstruction, and cardiopulmonary complications (e.g., pneumonia, myocardial infarction).

### Reoperation Rate

Reoperation may be required to “take down” or revise the original procedure. Reoperation may be particularly common in vertical-banded gastroplasty due to pouch dilation.

### Long-Term Complications (Metabolic Adverse Events, Nutritional Deficiencies)

Metabolic adverse events are of particular concern in malabsorptive procedures. Other long-term complications include anastomotic ulcers, esophagitis, and procedure-specific complications such as band erosion or migration for gastric banding surgeries.

### Improved Health Outcomes in Terms of Weight-Related Comorbidities

Aside from psychosocial concerns, which may be considerable, one motivation for bariatric surgery is to decrease the incidence of complications of obesity, such as diabetes, cardiovascular risk factors (i.e., increased cholesterol, hypertension), obstructive sleep apnea, or arthritis. Unfortunately, these final health outcomes are not consistently reported.

### REGULATORY STATUS

Forms of bariatric surgery performed without specific implantable devices are surgical procedures and, as such, are not subject to regulation by the FDA.

Table 2 shows forms of bariatric surgery with implantable devices approved by the FDA through the premarket approval process.

Table 2. FDA-Approved Bariatric Surgery Devices

Device	Manufacturer	PMA Date	Labeled Indications
AspireAssist System®	Aspire Bariatrics	Jun 2016	For long-term use in conjunction with lifestyle therapy and continuous medical monitoring in obese adults >22 y, with a BMI of 35.0 to 55.0 kg/m <sup>2</sup> and no contraindications to the procedure who have failed to achieve and maintain weight loss with nonsurgical weight loss therapy.
ORBERA® intragastric balloon system	Apollo Endosurgery	Aug 2015	For use in obese adults (BMI, 30-40 kg/m <sup>2</sup> ) who have failed weight reduction with diet and exercise, and have no contraindications. Maximum placement time is six months. Balloon placed endoscopically and inflated with saline.
ReShape® Integrated Dual Balloon System	ReShape Medical	Jul 2015	For use in obese adults (BMI, 30-40 kg/m <sup>2</sup> ) and ≥ one comorbid conditions who have failed weight reduction with diet and exercise, and have no contraindications. Maximum placement time is six months. Balloon delivered transorally and inflated with saline.
LAP-BAND® Adjustable Gastric Banding System	Apollo Endosurgery (original applicant: Allergan)	Apr 2010	For use in weight reduction for severely obese adults with BMI of at least 40 kg/m <sup>2</sup> or a BMI of at least 30 kg/m <sup>2</sup> with ≥ one severe comorbid conditions who have failed more conservative weight-reduction alternatives (e.g., supervised diet, exercise, behavior modification programs).
REALIZE® Adjustable Gastric Band	Ethicon Endosurgery	Nov 2007	For use in weight reduction for morbidly obese patients and for individuals with BMI of at least 40 kg/m <sup>2</sup> , or a BMI of at least 35 kg/m <sup>2</sup> with ≥1 comorbid conditions, or those who are ≥45.4 kg over their estimated ideal weight. Indicated for use only in morbidly obese adults who have failed more conservative weight-reduction alternatives (e.g., supervised diet, exercise, behavior modification programs).

BMI: body mass index; FDA: Food and Drug Administration; PMA: premarket approval.

In February 2017, the FDA issued a letter to health care providers discussing the potential risks with liquid-filled intragastric balloons in response to reports of two types of adverse events related to the balloons. Several dozen reports concerned spontaneous over inflation of the balloons, which caused pain, swelling, and vomiting. The second set of adverse event reports indicated that acute pancreatitis developed in several patients due to compression of gastrointestinal structures. These reports involved both ReShape and ORBERA brands. The adverse events may require premature removal of the balloons.

In August 2017, the FDA issued a second letter to health care providers informing them of five unanticipated deaths occurring from 2016 through the time of the letter, due to intragastric balloons. The FDA recommended close monitoring of patients receiving these devices.

## RELATED PROTOCOLS

Gastric Electrical Stimulation

Transesophageal Endoscopic Therapies for Gastroesophageal Reflux Disease

---

Services that are the subject of a clinical trial do not meet our Technology Assessment and Medically Necessary Services Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment and Medically Necessary Services Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

## REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. *Ann Intern Med.* Dec 15 1991;115(12):956-961. PMID 1952493
2. O'Brien PE, Sawyer SM, Laurie C, et al. Laparoscopic adjustable gastric banding in severely obese adolescents: a randomized trial. *JAMA.* Feb 10 2010;303(6):519-526. PMID 20145228
3. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. *N Engl J Med.* Aug 23 2007;357(8):741-752. PMID 17715408
4. Scopinaro N, Papadia F, Marinari G, et al. Long-term control of type 2 diabetes mellitus and the other major components of the metabolic syndrome after biliopancreatic diversion in patients with BMI <35 kg/m2. *Obes Surg.* Feb 2007;17(2):185-192. PMID 17476869
5. Sjostrom CD, Lissner L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. *Obes Res.* Sep 1999;7(5):477-484. PMID 10509605
6. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *N Engl J Med.* Dec 23 2004;351(26):2683-2693. PMID 15616203
7. Torgerson JS, Sjostrom L. The Swedish Obese Subjects (SOS) study--rationale and results. *Int J Obes Relat Metab Disord.* May 2001;25 Suppl 1:S2-4. PMID 11466577
8. Courcoulas AP, Christian NJ, Belle SH, et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. *JAMA.* Dec 11 2013;310(22):2416-2425. PMID 24189773
9. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. *JAMA.* Oct 13 2004;292(14):1724-1737. PMID 15479938
10. Maggard MA, Shugarman LR, Suttrop M, et al. Meta-analysis: surgical treatment of obesity. *Ann Intern Med.* Apr 5 2005;142(7):547-559. PMID 15809466
11. Kang JH, Le QA. Effectiveness of bariatric surgical procedures: A systematic review and network meta-analysis of randomized controlled trials. *Medicine (Baltimore).* Nov 2017;96(46):e8632. PMID 29145284
12. Colquitt JL, Pickett K, Loveman E, et al. Surgery for weight loss in adults. *Cochrane Database Syst Rev.* 2014;8:CD003641. PMID 25105982
13. Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. *BMJ.* Oct 22 2013;347:f5934. PMID 24149519

14. Chang SH, Stoll CR, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. *JAMA Surg.* Mar 2014;149(3):275-287. PMID 24352617
15. Wilhelm SM, Young J, Kale-Pradhan PB. Effect of bariatric surgery on hypertension: a meta-analysis. *Ann Pharmacother.* Jun 2014;48(6):674-682. PMID 24662112
16. Ricci C, Gaeta M, Rausa E, et al. Early impact of bariatric surgery on type II diabetes, hypertension, and hyperlipidemia: a systematic review, meta-analysis and meta-regression on 6,587 patients. *Obes Surg.* Apr 2014;24(4):522-528. PMID 24214202
17. Cuspidi C, Rescaldani M, Tadic M, et al. Effects of bariatric surgery on cardiac structure and function: a systematic review and meta-analysis. *Am J Hypertens.* Feb 2014;27(2):146-156. PMID 24321879
18. Kwok CS, Pradhan A, Khan MA, et al. Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. *Int J Cardiol.* Apr 15 2014;173(1):20-28. PMID 24636546
19. Afshar S, Kelly SB, Seymour K, et al. The effects of bariatric surgery on colorectal cancer risk: systematic review and meta-analysis. *Obes Surg.* Oct 2014;24(10):1793-1799. PMID 25015708
20. Andersen JR, Aasprang A, Karlsten TI, et al. Health-related quality of life after bariatric surgery: a systematic review of prospective long-term studies. *Surg Obes Relat Dis.* Mar-Apr 2015;11(2):466-473. PMID 25820082
21. Arterburn DE, Olsen MK, Smith VA, et al. Association between bariatric surgery and long-term survival. *JAMA.* Jan 6 2015;313(1):62-70. PMID 25562267
22. Bower G, Toma T, Harling L, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. *Obes Surg.* Dec 2015;25(12):2280-2289. PMID 25917981
23. Cheung D, Switzer NJ, Ehmann D, et al. The impact of bariatric surgery on diabetic retinopathy: a systematic review and meta-analysis. *Obes Surg.* Sep 2015;25(9):1604-1609. PMID 25515499
24. Driscoll S, Gregory DM, Fardy JM, et al. Long-term health-related quality of life in bariatric surgery patients: A systematic review and meta-analysis. *Obesity (Silver Spring).* Jan 2016;24(1):60-70. PMID 26638116
25. Groen VA, van de Graaf VA, Scholtes VA, et al. Effects of bariatric surgery for knee complaints in (morbidly) obese adult patients: a systematic review. *Obes Rev.* Feb 2015;16(2):161-170. PMID 25487972
26. Hachem A, Brennan L. Quality of life outcomes of bariatric surgery: a systematic review. *Obes Surg.* Feb 2016;26(2):395-409. PMID 26494369
27. Lindekilde N, Gladstone BP, Lubeck M, et al. The impact of bariatric surgery on quality of life: a systematic review and meta-analysis. *Obes Rev.* Aug 2015;16(8):639-651. PMID 26094664
28. Lopes EC, Heineck I, Athaydes G, et al. Is bariatric surgery effective in reducing comorbidities and drug costs? a systematic review and meta-analysis. *Obes Surg.* Sep 2015;25(9):1741-1749. PMID 26112137
29. Ricci C, Gaeta M, Rausa E, et al. Long-term effects of bariatric surgery on type II diabetes, hypertension and hyperlipidemia: a meta-analysis and meta-regression study with 5-year follow-up. *Obes Surg.* Mar 2015; 25(3):397-405. PMID 25240392
30. Yang XW, Li PZ, Zhu LY, et al. Effects of bariatric surgery on incidence of obesity-related cancers: a meta-analysis. *Med Sci Monit.* May 11 2015;21:1350-1357. PMID 25961664
31. Puzifferri N, Roshek TB, 3rd, Mayo HG, et al. Long-term follow-up after bariatric surgery: a systematic review. *JAMA.* Sep 3 2014;312(9):934-942. PMID 25182102
32. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). TEC Special Report: The relationship between weight loss and changes in morbidity following bariatric surgery for morbid obesity. *TEC Assessments.* 2003;Vol 18:Tab 18.
33. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Laparoscopic gastric bypass surgery for morbid obesity. *TEC Assessment.* 2005;Vol:Tab 15.
34. Yan Y, Sha Y, Yao G, et al. Roux-en-y gastric bypass versus medical treatment for type 2 diabetes mellitus in obese patients: a systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore).* Apr 2016;95(17):e3462. PMID 27124041
35. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Laparoscopic adjustable gastric banding for morbid obesity. *TEC Assessment.* 2006;Vol 21:Tab 13.

36. Ibrahim AM, Thumma JR, Dimick JB. Reoperation and Medicare expenditures after laparoscopic gastric band surgery. *JAMA Surg.* Sep 1 2017;152(9):835-842. PMID 28514487
37. Chakravarty PD, McLaughlin E, Whittaker D, et al. Comparison of laparoscopic adjustable gastric banding (LAGB) with other bariatric procedures; a systematic review of the randomised controlled trials. *Surgeon.* Jun 2012;10(3):172-182. PMID 22405735
38. Dixon JB, Eaton LL, Curry T, et al. Health Outcomes and Explant Rates After Laparoscopic Adjustable Gastric Banding: A Phase 4, Multicenter Study over 5 Years. *Obesity (Silver Spring).* 2018 Jan;26(1):45-52. PMID: 29265773
39. Osland E, Yunus RM, Khan S, et al. Weight loss outcomes in laparoscopic vertical sleeve gastrectomy (LVSG) versus laparoscopic roux-en-y gastric bypass (LRYGB) procedures: a meta-analysis and systematic review of randomized controlled trials. *Surg Laparosc Endosc Percutan Tech.* Feb 2017;27(1):8-18. PMID 28145963
40. Juodeikis Z, Brimas G. Long-term results after sleeve gastrectomy: A systematic review. *Surg Obes Relat Dis.* Apr 2017;13(4):693-699. PMID 27876332
41. Zhang Y, Wang J, Sun X, et al. Laparoscopic sleeve gastrectomy versus laparoscopic Roux-en-Y gastric bypass for morbid obesity and related comorbidities: a meta-analysis of 21 studies. *Obes Surg.* Jan 2015; 25(1):19-26. PMID 25092167
42. Trastulli S, Desiderio J, Guarino S, et al. Laparoscopic sleeve gastrectomy compared with other bariatric surgical procedures: a systematic review of randomized trials. *Surg Obes Relat Dis.* Sep-Oct 2013;9(5):816-829. PMID 23993246
43. Brethauer SA, Hammel JP, Schauer PR. Systematic review of sleeve gastrectomy as staging and primary bariatric procedure. *Surg Obes Relat Dis.* Jul-Aug 2009;5(4):469-475. PMID 19632646
44. Peterli R, Wölnerhanssen BK, Peters T, et al. Effect of Laparoscopic Sleeve Gastrectomy vs. Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. *JAMA.* 2018 Jan 16;319(3):255-265. PMID: 29340679
45. Salminen P, Helmiö M, Ovaska J, et al. Effect of Laparoscopic Sleeve Gastrectomy vs. Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial. *JAMA.* 2018 Jan 16;319(3):241-254. PMID: 29340676
46. Helmiö M, Victorzon M, Ovaska J, et al. SLEEVEPASS: a randomized prospective multicenter study comparing laparoscopic sleeve gastrectomy and gastric bypass in the treatment of morbid obesity: preliminary results. *Surg Endosc.* Sep 2012;26(9):2521-2526. PMID 22476829
47. Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. *Ann Surg.* Mar 2008;247(3):401-407. PMID 18376181
48. Himpens J, Dapri G, Cadiere GB. A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years. *Obes Surg.* Nov 2006;16(11):1450-1456. PMID 17132410
49. Farrell TM, Haggerty SP, Overby DW, et al. Clinical application of laparoscopic bariatric surgery: an evidence-based review. *Surg Endosc.* May 2009;23(5):930-949. PMID 19125308
50. Skogar ML, Sundbom M. Duodenal switch is superior to gastric bypass in patients with super obesity when evaluated with the Bariatric Analysis and Reporting Outcome System (BAROS). *Obes Surg.* Sep 2017;27(9): 2308-2316. PMID 28439748
51. Strain GW, Gagner M, Inabnet WB, et al. Comparison of effects of gastric bypass and biliopancreatic diversion with duodenal switch on weight loss and body composition 1-2 years after surgery. *Surg Obes Relat Dis.* Jan- Feb 2007;3(1):31-36. PMID 17116424
52. Prachand VN, Davee RT, Alverdy JC. Duodenal switch provides superior weight loss in the super-obese (BMI > or =50 kg/m<sup>2</sup>) compared with gastric bypass. *Ann Surg.* Oct 2006;244(4):611-619. PMID 16998370
53. Strain GW, Torghabeh MH, Gagner M, et al. Nutrient status 9 years after biliopancreatic diversion with duodenal switch (BPD/DS): an observational study. *Obes Surg.* Jul 2017;27(7):1709-1718. PMID 28155056

54. Marceau P, Biron S, Hould FS, et al. Duodenal switch improved standard biliopancreatic diversion: a retrospective study. *Surg Obes Relat Dis*. Jan-Feb 2009;5(1):43-47. PMID 18440876
55. Slater GH, Ren CJ, Siegel N, et al. Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. *J Gastrointest Surg*. Jan 2004;8(1):48-55; discussion 54-45. PMID 14746835
56. Dolan K, Hatzifotis M, Newbury L, et al. A clinical and nutritional comparison of biliopancreatic diversion with and without duodenal switch. *Ann Surg*. Jul 2004;240(1):51-56. PMID 15213618
57. Skroubis G, Anesidis S, Kehagias I, et al. Roux-en-Y gastric bypass versus a variant of biliopancreatic diversion in a non-superobese population: prospective comparison of the efficacy and the incidence of metabolic deficiencies. *Obes Surg*. Apr 2006;16(4):488-495. PMID 16608616
58. Scopinaro N, Gianetta E, Adami GF, et al. Biliopancreatic diversion for obesity at eighteen years. *Surgery*. Mar 1996;119(3):261-268. PMID 8619180
59. Balsiger BM, Poggio JL, Mai J, et al. Ten and more years after vertical banded gastroplasty as primary operation for morbid obesity. *J Gastrointest Surg*. Nov-Dec 2000;4(6):598-605. PMID 11307094
60. Miller K, Pump A, Hell E. Vertical banded gastroplasty versus adjustable gastric banding: prospective long-term follow-up study. *Surg Obes Relat Dis*. Jan-Feb 2007;3(1):84-90. PMID 17116427
61. Hsieh T, Zurita L, Grover H, et al. 10-year outcomes of the vertical transected gastric bypass for obesity: a systematic review. *Obes Surg*. Mar 2014;24(3):456-461. PMID 24379176
62. Hall JC, Watts JM, O'Brien PE, et al. Gastric surgery for morbid obesity. The Adelaide Study. *Ann Surg*. Apr 1990;211(4):419-427. PMID 2181950
63. Sugerma HJ, Starkey JV, Birkenhauer R. A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters. *Ann Surg*. Jun 1987;205(6):613-624. PMID 3296971
64. MacLean LD, Rhode BM, Forse RA. Late results of vertical banded gastroplasty for morbid and super obesity. *Surgery*. Jan 1990;107(1):20-27. PMID 2296754
65. Coffin B, Maunoury V, Pattou F, et al. Impact of intragastric balloon before laparoscopic gastric bypass on patients with super obesity: a randomized multicenter study. *Obes Surg*. Apr 2017;27(4):902-909. PMID 27664095
66. Cottam D, Qureshi FG, Mattar SG, et al. Laparoscopic sleeve gastrectomy as an initial weight-loss procedure for high-risk patients with morbid obesity. *Surg Endosc*. Jun 2006;20(6):859-863. PMID 16738970
67. Alexandrou A, Felekouras E, Giannopoulos A, et al. What is the actual fate of super-morbid-obese patients who undergo laparoscopic sleeve gastrectomy as the first step of a two-stage weight-reduction operative strategy? *Obes Surg*. Jul 26 2012;22(10):1623-1628. PMID 22833137
68. Silecchia G, Rizzello M, Casella G, et al. Two-stage laparoscopic biliopancreatic diversion with duodenal switch as treatment of high-risk super-obese patients: analysis of complications. *Surg Endosc*. May 2009; 23(5):1032-1037. PMID 18814005
69. Ji Y, Wang Y, Zhu J, et al. A systematic review of gastric plication for the treatment of obesity. *Surg Obes Relat Dis*. Nov-Dec 2014;10(6):1226-1232. PMID 24582413
70. Talebpour M, Motamedi SM, Talebpour A, et al. Twelve year experience of laparoscopic gastric plication in morbid obesity: development of the technique and patient outcomes. *Ann Surg Innov Res*. Aug 22 2012; 6(1):7. PMID 22913751
71. Abdelbaki TN, Huang CK, Ramos A, et al. Gastric plication for morbid obesity: a systematic review. *Obes Surg*. Oct 2012;22(10):1633-1639. PMID 22960951
72. Sullivan S, Swain JM, Woodman G, et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: The ESSENTIAL trial. *Obesity (Silver Spring)*. Feb 2017; 25(2):294-301. PMID 28000425
73. Talebpour M, Sadid D, Talebpour A, et al. Comparison of short-term effectiveness and postoperative complications: laparoscopic gastric plication vs. laparoscopic sleeve gastrectomy. *Obes Surg*. Oct 17 2017. PMID 29043548

74. Pattanshetti S, Tai CM, Yen YC, et al. Laparoscopic adjustable gastric banded plication: evolution of procedure and 2-year results. *Obes Surg.* Nov 2013;23(11):1934-1938. PMID 24013809
75. Sanchez-Pernaute A, Rubio MA, Cabrerizo L, et al. Single-anastomosis duodenoileal bypass with sleeve gastrectomy (SADI-S) for obese diabetic patients. *Surg Obes Relat Dis.* Sep-Oct 2015;11(5):1092-1098. PMID 26048517
76. Torres A, Rubio MA, Ramos-Levi AM, et al. Cardiovascular risk factors after single anastomosis duodenoileal bypass with sleeve gastrectomy (SADI-S): a new effective therapeutic approach? *Curr Atheroscler Rep.* Nov 7 2017;19(12):58. PMID 29116413
77. Rohde U, Hedback N, Gluud LL, et al. Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab.* Mar 2016;18(3):300-305. PMID 26537317
78. Koehestanie P, de Jonge C, Berends FJ, et al. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. *Ann Surg.* Dec 2014;260(6):984-992. PMID 25072436
79. Saber AA, Shoar S, Almadani MW, et al. Efficacy of first-time intragastric balloon in weight loss: a systematic review and meta-analysis of randomized controlled trials. *Obes Surg.* Feb 2017;27(2):277-287. PMID 27465936
80. Moura D, Oliveira J, De Moura EG, et al. Effectiveness of intragastric balloon for obesity: A systematic review and meta-analysis based on randomized control trials. *Surg Obes Relat Dis.* Feb 2016;12(2):420-429. PMID 26968503
81. Zheng Y, Wang M, He S, et al. Short-term effects of intragastric balloon in association with conservative therapy on weight loss: a meta-analysis. *J Transl Med.* Jul 29 2015;13:246. PMID 26219459
82. Tate CM, Geliebter A. Intragastric balloon treatment for obesity: review of recent studies. *Adv Ther.* Aug 2017;34(8):1859-1875. PMID 28707286
83. Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. *Surg Obes Relat Dis.* Jul-Aug 2015;11(4):874-881. PMID 25868829
84. Courcoulas A, Abu Dayyeh BK, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. *Int J Obes (Lond).* Mar 2017;41(3):427-433. PMID 28017964
85. Genco A, Cipriano M, Bacci V, et al. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. *Int J Obes (Lond).* Jan 2006;30(1):129-133. PMID 16189503
86. Kotzampassi K, Grosomanidis V, Papakostas P, et al. 500 intragastric balloons: what happens 5 years thereafter? *Obes Surg.* Jun 2012;22(6):896-903. PMID 22287051
87. Thompson CC, Abu Dayyeh BK, Kushner R, et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. *Am J Gastroenterol.* Mar 2017;112(3):447-457. PMID 27922026
88. Noren E, Forssell H. Aspiration therapy for obesity; a safe and effective treatment. *BMC Obes.* Dec 2016; 3:56. PMID 28035287
89. Almalki OM, Lee WJ, Chen JC, et al. Revisional Gastric Bypass for Failed Restrictive Procedures: Comparison of Single-Anastomosis (Mini-) and Roux-en-Y Gastric Bypass. *Obes Surg.* 2018 Apr;28(4):970-975. PMID: 29101719
90. Sudan R, Nguyen NT, Hutter MM, et al. Morbidity, mortality, and weight loss outcomes after reoperative bariatric surgery in the USA. *J Gastrointest Surg.* Jan 2015;19(1):171-178; discussion 178-179. PMID 25186073
91. Brethauer SA, Kothari S, Sudan R, et al. Systematic review on reoperative bariatric surgery: American Society for Metabolic and Bariatric Surgery Revision Task Force. *Surg Obes Relat Dis.* Sep-Oct 2014;10(5):952-972. PMID 24776071

92. Catalano MF, Rudic G, Anderson AJ, et al. Weight gain after bariatric surgery as a result of a large gastric stoma: endotherapy with sodium morrhuate may prevent the need for surgical revision. *Gastrointest Endosc.* Aug 2007;66(2):240-245. PMID 17331511
93. Herron DM, Birkett DH, Thompson CC, et al. Gastric bypass pouch and stoma reduction using a transoral endoscopic anchor placement system: a feasibility study. *Surg Endosc.* Apr 2008;22(4):1093-1099. PMID 18027049
94. Thompson CC, Slattery J, Bundga ME, et al. Peroral endoscopic reduction of dilated gastrojejunal anastomosis after Roux-en-Y gastric bypass: a possible new option for patients with weight regain. *Surg Endosc.* Nov 2006;20(11):1744-1748. PMID 17024527
95. Eid GM, McCloskey CA, Eagleton JK, et al. StomaphyX vs. a sham procedure for revisional surgery to reduce regained weight in Roux-en-Y gastric bypass patients: a randomized clinical trial. *JAMA Surg.* Apr 2014; 149(4):372-379. PMID 24554030
96. Brethauer SA, Pryor AD, Chand B, et al. Endoluminal procedures for bariatric patients: expectations among bariatric surgeons. *Surg Obes Relat Dis.* Mar-Apr 2009;5(2):231-236. PMID 19136306
97. Dakin GF, Eid G, Mikami D, et al. Endoluminal revision of gastric bypass for weight regain--a systematic review. *Surg Obes Relat Dis.* May-Jun 2013;9(3):335-342. PMID 23561960
98. Wu GZ, Cai B, Yu F, et al. Meta-analysis of bariatric surgery versus non-surgical treatment for type 2 diabetes mellitus. *Oncotarget.* Dec 27 2016;7(52):87511-87522. PMID 27626180
99. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. *Lancet.* Sep 05 2015;386(9997):964-973. PMID 26369473
100. Muller-Stich BP, Senft JD, Warschkow R, et al. Surgical versus medical treatment of type 2 diabetes mellitus in non-severely obese patients: a systematic review and meta-analysis. *Ann Surg.* Mar 2015;261(3):421-429. PMID 25405560
101. Rao WS, Shan CX, Zhang W, et al. A meta-analysis of short-term outcomes of patients with type 2 diabetes mellitus and BMI
102. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Bariatric Surgery In Patients With Diabetes And Body Mass Index Less Than 35 kg/m2 TEC Assessments. 2012;Volume 27:Tab 2.
103. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. *JAMA.* Jan 23 2008;299(3):316-323. PMID 18212316
104. Ikramuddin S, Billington CJ, Lee WJ, et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. *Lancet Diabetes Endocrinol.* Jun 2015; 3(6):413-422. PMID 25979364
105. Liang Z, Wu Q, Chen B, et al. Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. *Diabetes Res Clin Pract.* Jul 2013;101(1):50-56. PMID 23706413
106. Courcoulas AP, Belle SH, Neiberg RH, et al. Three-year outcomes of bariatric surgery vs. lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial. *JAMA Surg.* Oct 2015;150(10):931-940. PMID 26132586
107. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. *N Engl J Med.* Feb 16 2017;376(7):641-651. PMID 28199805
108. Wentworth JM, Playfair J, Laurie C, et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial. *Lancet Diabetes Endocrinol.* Jul 2014;2(7):545-552. PMID 24731535
109. Halperin F, Ding SA, Simonson DC, et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. *JAMA Surg.* Jul 2014;149(7):716-726. PMID 24899464
110. Scopinaro N, Adami GF, Papadia FS, et al. Effects of gastric bypass on type 2 diabetes in patients with BMI 30 to 35. *Obes Surg.* Jul 2014;24(7):1036-1043. PMID 24647849

111. Lanzarini E, Csendes A, Gutierrez L, et al. Type 2 diabetes mellitus in patients with mild obesity: preliminary results of surgical treatment. *Obes Surg*. Feb 2013;23(2):234-240. PMID 23054574
112. Boza C, Munoz R, Salinas J, et al. Safety and efficacy of Roux-en-Y gastric bypass to treat type 2 diabetes mellitus in non-severely obese patients. *Obes Surg*. Sep 2011;21(9):1330-1336. PMID 21744283
113. DePaula AL, Stival AR, DePaula CC, et al. Surgical treatment of type 2 diabetes in patients with BMI below 35: mid-term outcomes of the laparoscopic ileal interposition associated with a sleeve gastrectomy in 202 consecutive cases. *J Gastrointest Surg*. May 2012;16(5):967-976. PMID 22350720
114. Lee WJ, Wang W, Lee YC, et al. Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI>35 and <35 kg/m<sup>2</sup>. *J Gastrointest Surg*. May 2008;12(5):945-952. PMID 17940829
115. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Laparoscopic adjustable gastric banding in patients with body mass index less than 35 kg/m<sup>2</sup> with weight-related comorbidity. *TEC Assessments*. 2012;Volume 27:Tab 3.
116. Qi L, Guo Y, Liu CQ, et al. Effects of bariatric surgery on glycemic and lipid metabolism, surgical complication and quality of life in adolescents with obesity: a systematic review and meta-analysis. *Surg Obes Relat Dis*. Dec 2017;13(12):2037-2055. PMID 29079384
117. Black JA, White B, Viner RM, et al. Bariatric surgery for obese children and adolescents: a systematic review and meta-analysis. *Obes Rev*. Aug 2013;14(8):634-644. PMID 23577666
118. Treadwell JR, Sun F, Schoelles K. Systematic review and meta-analysis of bariatric surgery for pediatric obesity. *Ann Surg*. Nov 2008;248(5):763-776. PMID 18948803
119. Dumont PN, Blanchet MC, Gignoux B, Matussière Y, Frering V. Medium- to Long-Term Outcomes of Gastric Banding in Adolescents: a Single-Center Study of 97 Consecutive Patients. *Obes Surg*. 2018 Jan;28(1):285-289. PMID: 29103071
120. Inge TH, Zeller MH, Jenkins TM, et al. Perioperative outcomes of adolescents undergoing bariatric surgery: the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study. *JAMA Pediatr*. Jan 2014;168(1):47-53. PMID 24189578
121. Olbers T, Beamish AJ, Gronowitz E, et al. Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish nationwide study. *Lancet Diabetes Endocrinol*. Mar 2017; 5(3):174-183. PMID 28065734
122. Willcox K, Brennan L. Biopsychosocial outcomes of laparoscopic adjustable gastric banding in adolescents: a systematic review of the literature. *Obes Surg*. Sep 2014;24(9):1510-1519. PMID 24849913
123. Nadler EP, Youn HA, Ren CJ, et al. An update on 73 US obese pediatric patients treated with laparoscopic adjustable gastric banding: comorbidity resolution and compliance data. *J Pediatr Surg*. Jan 2008;43(1):141-146. PMID 18206472
124. Manco M, Mosca A, De Peppo F, et al. The benefit of sleeve gastrectomy in obese adolescents on nonalcoholic steatohepatitis and hepatic fibrosis. *J Pediatr*. Jan 2017;180:31-37 e32. PMID 27697327
125. Alqahtani AR, Antonisamy B, Alamri H, et al. Laparoscopic sleeve gastrectomy in 108 obese children and adolescents aged 5 to 21 years. *Ann Surg*. Aug 2012;256(2):266-273. PMID 22504281
126. August GP, Caprio S, Fennoy I, et al. Prevention and treatment of pediatric obesity: an Endocrine Society clinical practice guideline based on expert opinion. *J Clin Endocrinol Metab*. Dec 2008;93(12):4576-4599. PMID 18782869
127. Fitch A, Fox C, Bauerly K, et al. Health Care Guideline: Prevention and Management of Obesity for Children and Adolescents. Institute for Clinical Systems Improvement. 2013; <https://www.ohcoop.org/wp-content/uploads/Clinical-Guidelines-Prevention-and-Management-Obesity-in-Children-and-Adolscent.pdf>. Accessed January 11, 2018.
128. Greenstein RJ, Nissan A, Jaffin B. Esophageal anatomy and function in laparoscopic gastric restrictive bariatric surgery: implications for patient selection. *Obes Surg*. Apr 1998;8(2):199-206. PMID 9730394
129. Pilone V, Vitiello A, Hasani A, et al. Laparoscopic adjustable gastric banding outcomes in patients with gastroesophageal reflux disease or hiatal hernia. *Obes Surg*. Feb 2015;25(2):290-294. PMID 25030091

130. Kohn GP, Price RR, DeMeester SR, et al. Guidelines for the management of hiatal hernia. *Surg Endosc*. Dec 2013;27(12):4409-4428. PMID 24018762
131. Gulkarov I, Wetterau M, Ren CJ, et al. Hiatal hernia repair at the initial laparoscopic adjustable gastric band operation reduces the need for reoperation. *Surg Endosc*. Apr 2008;22(4):1035-1041. PMID 18080712
132. Santonicola A, Angrisani L, Cutolo P, et al. The effect of laparoscopic sleeve gastrectomy with or without hiatal hernia repair on gastroesophageal reflux disease in obese patients. *Surg Obes Relat Dis*. Mar-Apr 2014;10(2):250-255. PMID 24355324
133. Reynoso JF, Goede MR, Tiwari MM, et al. Primary and revisional laparoscopic adjustable gastric band placement in patients with hiatal hernia. *Surg Obes Relat Dis*. May-Jun 2011;7(3):290-294. PMID 21130046
134. Ardestani A, Tavakkoli A. Hiatal hernia repair and gastroesophageal reflux disease in gastric banding patients: analysis of a national database. *Surg Obes Relat Dis*. May-Jun 2014;10(3):438-443. PMID 24680760
135. Frezza EE, Barton A, Wachtel MS. Crural repair permits morbidly obese patients with not large hiatal hernia to choose laparoscopic adjustable banding as a bariatric surgical treatment. *Obes Surg*. May 2008;18(5):583-588. PMID 18317857
136. al-Haddad BJ, Dorman RB, Rasmus NF, et al. Hiatal hernia repair in laparoscopic adjustable gastric banding and laparoscopic Roux-en-Y gastric bypass: a national database analysis. *Obes Surg*. Mar 2014;24(3):377-384. PMID 24307434
137. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2017 Executive Summary. *Endocr Pract*. Feb 2017;23(2):207-238. PMID 28095040
138. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Executive summary. *Endocr Pract*. Jul 2016;22(7):842-884. PMID 27472012
139. Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. *Surg Obes Relat Dis*. Mar-Apr 2013;9(2):159-191. PMID 23537696
140. Executive summary: Guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the The Obesity Expert Panel, 2013. *Obesity (Silver Spring)*. Jul 2014;22 Suppl 2:S5-39. PMID 24961825
141. Ali MR, Moustarah F, Kim JJ, et al. American Society for Metabolic and Bariatric Surgery position statement on intragastric balloon therapy endorsed by the Society of American Gastrointestinal and Endoscopic Surgeons. *Surg Obes Relat Dis*. Mar-Apr 2016;12(3):462-467. PMID 27056407
142. ASMBS Clinical Issues Committee. Updated position statement on sleeve gastrectomy as a bariatric procedure. *Surg Obes Relat Dis*. May-Jun 2012;8(3):e21-26. PMID 22417852
143. Childerhose JE, Alsamawi A, Mehta T, et al. Adolescent bariatric surgery: a systematic review of recommendation documents. *Surg Obes Relat Dis*. Oct 2017;13(10):1768-1779. PMID 28958402
144. Michalsky M, Reichard K, Inge T, et al. ASMBS pediatric committee best practice guidelines. *Surg Obes Relat Dis*. Jan-Feb 2012;8(1):1-7. PMID 22030146
145. Nobili V, Vajro P, Dezsófi A, et al. Indications and limitations of bariatric intervention in severely obese children and adolescents with and without nonalcoholic steatohepatitis: ESPGHAN Hepatology Committee Position Statement. *J Pediatr Gastroenterol Nutr*. Apr 2015;60(4):550-561. PMID 25591123
146. Styne DM, Arslanian SA, Connor EL, et al. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. Mar 1 2017;102(3):709-757. PMID 28359099

147. Aikenhead A, Lobstein T, Knai C. Review of current guidelines on adolescent bariatric surgery. *Clin Obes.* Feb 2011;1(1):3-11. PMID 25586970
148. Centers for Medicare and Medicaid Services (CMS). Decision Memo for Bariatric Surgery for the Treatment of Morbid Obesity (CAG-00250R). 2006; [https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=160&NcaName=Bariatric+Surgery+for+the+Treatment+of+Morbid+Obesity+\(1st+Recon\)&b c=ACAAAAAAEAAA&](https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=160&NcaName=Bariatric+Surgery+for+the+Treatment+of+Morbid+Obesity+(1st+Recon)&b c=ACAAAAAAEAAA&). Accessed January 11, 2018.